The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis.
Open Access
- 1 July 1998
- journal article
- case report
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 134 (7) , 785-786
- https://doi.org/10.1001/archderm.134.7.785
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter studyClinical Therapeutics, 1997
- Recent developments in the treatment of atopic eczemaJournal of the American Academy of Dermatology, 1997
- Leukotrienes in the Pathogenesis of AsthmaChest, 1997
- The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis.American Journal of Respiratory and Critical Care Medicine, 1995
- Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.American Journal of Respiratory and Critical Care Medicine, 1994
- The effect of the oral leukotriene antagonist, ICI 204,219, on leukotriene D and histamine-induced cutaneous vascular reactions in manJournal of Allergy and Clinical Immunology, 1991